Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center. (3rd April 2021)

• Record Type: Journal Article
• Authors: Giuffrè, Chiara; Cicinelli, Maria Vittoria; Marchese, Alessandro; Modorati, Giulio M.; Brambati, Maria; Ferreri, Andrés J. M.; Calimeri, Teresa; Ponzoni, Maurilio; Bandello, Francesco; Miserocchi, Elisabetta
• Is Part Of: Ocular immunology and inflammation. Volume 29:Number 3(2021)
• Page Start: 472
• Page End: 478
• Publication Date: 2021-04-03
• Subjects: CNS lymphoma -- intravitreal chemotherapy -- multimodal imaging -- oncology -- uveitis -- vitreoretinal lymphoma; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2020.1787460
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Background/aims : To report our five-year experience on vitreoretinal lymphoma (VRL) as a single-center tertiary hospital. Methods : The ophthalmic, cytopathology, and onco-hematologic records of patients with VRL consecutively seen from 2014 to 2019 were reviewed. Results : Fifty-nine eyes of 31 patients with large B-cell VRL were included. Eighty-one percent has developed central nervous system lymphoma at the end of follow-up. Several different imaging findings were noted, including vitritis, leopard spot appearance, Bruch's membrane/RPE infiltrations, and ellipsoid zone disruption. A variable combination of MYD88-L265P mutation in the aqueous and/or in the vitreous and positive cytology/histology allowed to reach a definite diagnosis in all the patients. Therapies included intravitreal injections of methotrexate and rituximab, systemic chemotherapy, pan-encephalic radiotherapy, and hematopoietic stem cell transplantation. Conclusion : No definite guidelines exist for VRL management. It is crucial to collect as much data as possible from tertiary referral hospitals, which suitably manage a conspicuous number of VRL patients.